# RMC-6236

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/rmc-6236
Canonical HTML page: https://getbiobrief.com/entity/rmc-6236

## Timeline

- **2026-08-05**: Moderna flu vaccine PDUFA date — FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
- **2025-12**: Axsome full-year 2025 results — Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
- **2025-06**: Revolution Medicines mid-2025 data readout — RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.

## Recent coverage (2 stories)

### Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
2026-07-07 06:57:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Full story: https://getbiobrief.com/story/biotech-outperform-moderna-pdufa-revolution-axsome

### Erasca's Pan-RAS Drug ERAS-0015 Hit by IP War, Patient Death, $2.8B Loss
2026-06-16 14:03:32 · Sentiment: Strongly negative · Impact: 7/10 · Sources: 2

Revolution Medicines' patent infringement claim and a patient death have derailed Erasca's lead candidate, cutting its valuation by $2.8B. The biotech now faces a class action over alleged misrepresentations.
Full story: https://getbiobrief.com/story/erasca-eras-0015-ip-death-2-8b-lawsuit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.